knowledge -WSS

knowledge

author：fashion 2025-08-19 20:45:19 - browse：4158

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： SAMSHA loosens regulations on methadone treatment centers

leisure time

WSS

Pharma patents targeted by Biden in move to slash drug prices

Congressmen charge Covid hearing ‘could have been an email’

FDA drug safety: Singulair case shows systemic surveillance flaws

Cybersecurity threat forces Lurie Children's to take systems offline

SCOTUS to consider access to abortion pill mifepristone

Quicker fix for pulse oximeters urged during FDA public meeting

explore

knowledge

Wikipedia

Drug repurposing or repositioning? The language matters

FDA needs staff influx to meet gene therapy needs, Marks says

Alkermes shareholders re

FDA drug safety: Singulair case shows systemic surveillance flaws

Medicare proposal to cover medical devices draws a mixed reaction

Patients' immediate access to test results puts radiologists in a bind

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Covid misinformation case heads to Supreme Court

Medical leaders decry Supreme Court decision on affirmative action

Chemotherapy shortages won’t get better under Biden’s latest plan

entertainment

Congressmen charge Covid hearing ‘could have been an email’

Quicker fix for pulse oximeters urged during FDA public meeting

FDA approves world's first CRISPR

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Congressmen charge Covid hearing ‘could have been an email’

Pharma patents targeted by Biden in move to slash drug prices

Wikipedia

knowledge

leisure time

hotspot